The introduction of BTK inhibitors as part of the treatment regimen in chronic lymphatic leukemia (CLL), lymphoplasmacytic lymphoma (LPL) and mantle cell lymphoma (MCL) has been very successful [2]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.